Literature DB >> 26224289

Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Gerald A Dienel1, Nancy F Cruz2.   

Abstract

Phenylketonuria and hyperphenylalanemia are inborn errors in metabolism of phenylalanine arising from defects in steps to convert phenylalanine to tyrosine. Phe accumulation causes severe mental retardation that can be prevented by timely identification of affected individuals and their placement on a Phe-restricted diet. In spite of many studies in patients and animal models, the basis for acquisition of mental retardation during the critical period of brain development is not adequately understood. All animal models for human disease have advantages and limitations, and characteristics common to different models are most likely to correspond to the disorder. This study established similar levels of Phe exposure in developing rats between 3 and 16 days of age using three models to produce chronic hyperphenylalanemia, and identified changes in brain amino acid levels common to all models that persist for ~16 h of each day. In a representative model, local rates of glucose utilization (CMRglc) were determined at 25-27 days of age, and only selective changes that appeared to depend on Phe exposure were observed. CMRglc was reduced in frontal cortex and thalamus and increased in hippocampus and globus pallidus. Behavioral testing to evaluate neuromuscular competence revealed poor performance in chronically-hyperphenylalanemic rats that persisted for at least 3 weeks after cessation of Phe injections and did not occur with mild or acute hyperphenylalanemia. Thus, the abnormal amino acid environment, including hyperglycinemia, in developing rat brain is associated with selective regional changes in glucose utilization and behavioral abnormalities that are not readily reversed after they are acquired.

Entities:  

Keywords:  Amino acids; Behavior; Brain development; Glucose utilization; Hyperglycinemia; Hyperphenylalaninemia; Phenylketonuria

Mesh:

Substances:

Year:  2015        PMID: 26224289      PMCID: PMC4733436          DOI: 10.1007/s11064-015-1678-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  92 in total

1.  Manometric determination of L-aspartic acid and L-asparagine.

Authors:  H A KREBS
Journal:  Biochem J       Date:  1950 Nov-Dec       Impact factor: 3.857

2.  Glutamine in the phenylketonuric central nervous system.

Authors:  C M McKean; N A Peterson
Journal:  N Engl J Med       Date:  1970-12-17       Impact factor: 91.245

3.  Long-term changes in glutamatergic synaptic transmission in phenylketonuria.

Authors:  A V Glushakov; O Glushakova; M Varshney; L K Bajpai; C Sumners; P J Laipis; J E Embury; S P Baker; D H Otero; D M Dennis; C N Seubert; A E Martynyuk
Journal:  Brain       Date:  2005-01-05       Impact factor: 13.501

Review 4.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

5.  Chronic hyperphenylalaninemia produces cerebral hyperglycinemia in immature rats.

Authors:  G A Dienel
Journal:  J Neurochem       Date:  1981-01       Impact factor: 5.372

6.  Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels.

Authors:  Anatoly E Martynyuk; Deniz A Ucar; Dawn D Yang; Wendy M Norman; Paul R Carney; Donn M Dennis; Philip J Laipis
Journal:  Epilepsia       Date:  2007-05-01       Impact factor: 5.864

7.  Plasticity in the rat hippocampal formation following ibotenic acid lesion of the septal region: a quantitative [14C]deoxyglucose and acetylcholinesterase study.

Authors:  J B Schulz; A Wree; A Schleicher; K Zilles
Journal:  J Cereb Blood Flow Metab       Date:  1992-11       Impact factor: 6.200

8.  In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy.

Authors:  E J Novotny; M J Avison; N Herschkowitz; O A Petroff; J W Prichard; M R Seashore; D L Rothman
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

9.  Inhibition of glycine oxidation by pyruvate, alpha-ketoglutarate, and branched-chain alpha-keto acids in rat liver mitochondria: presence of interaction between the glycine cleavage system and alpha-keto acid dehydrogenase complexes.

Authors:  H Kochi; H Seino; K Ono
Journal:  Arch Biochem Biophys       Date:  1986-09       Impact factor: 4.013

Review 10.  Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia.

Authors:  Goro Kikuchi; Yutaro Motokawa; Tadashi Yoshida; Koichi Hiraga
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2008       Impact factor: 3.493

View more
  3 in total

1.  cAMP/PKA-CREB-BDNF signaling pathway in hippocampus of rats subjected to chemically-induced phenylketonuria.

Authors:  Cigdem Cicek; Emine Eren-Koçak; Pelin Telkoparan-Akillilar; Muslum Gok; Ebru Bodur
Journal:  Metab Brain Dis       Date:  2021-11-20       Impact factor: 3.584

Review 2.  Metabolic etiologies in West syndrome.

Authors:  Seda Salar; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia Open       Date:  2018-03-14

3.  A Retrospective Case Series Analysis of the Relationship Between Phenylalanine: Tyrosine Ratio and Cerebral Glucose Metabolism in Classical Phenylketonuria and Hyperphenylalaninemia.

Authors:  Colm J McGinnity; Daniela A Riaño Barros; Eric Guedj; Nadine Girard; Christopher Symeon; Helen Walker; Sally F Barrington; Mary Summers; Mervi Pitkanen; Yusof Rahman
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.